FINRISK 2002 Re-examination

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06284772

Enrollment

2500

Registered

2024-02-29

Start date

2023-11-13

Completion date

2024-06-25

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiometabolic Syndrome, Cardiovascular Diseases

Brief summary

The project aims to fill in the existing gaps in the study of the microbiome as a cardiometabolic driver 1) by determining the key demographic, environmental, genetic, dietary, and metabolic correlates of long-term within-individual microbiome and microbial metabolite changes; and 2) by assessing how the gut microbiome, microbial metabolites, and their long-term changes are prospectively related to the risk factors, surrogate markers, and overt outcomes of CMD. To achieve this goal, repeat stool samples will be collected of \ 2300 Finnish individuals who gave stool samples in the year 2002. In addition, \ 300 individuals will undergo a in-depth health examination in 2024.

Interventions

OTHERQuestionnaire and fecal sampling

The participants will be mailed a fecal collection kit and a 20-page health questionnaire. This questionnaire will include the similar questions concerning health, lifestyles, and diet as in 2002.

OTHERHealth examination

This examination will include measurements for anthropometrics, cognition (MoCA, Stroop, DSST), and blood pressure. The participants will undergo blood draw for laboratory analyses of CMD risk factors, such as blood lipids, glucose metabolism (fasting glucose, HbA1c, and fasting insulin), liver enzymes (GGT, ALT, and AST), inflammation (hs-CRP), and cardiac markers (proBNP and hs-TnI). We will perform ultrasound imaging for hepatic fibrosis.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

47 Years to 96 Years

Healthy volunteers

Yes

Inclusion criteria

* Participation in FINRISK 2002 fecal sampling

Design outcomes

Primary

Measure	Time frame	Description
Gut microbiome change between 2002-2024	2002-2024	Individual-level changes in the metagenome-sequenced gut microbiome between 2002 and 2024. The microbiome indices of interest are: 1. Alpha diversity 2. Beta diversity 3. Taxonomy

Secondary

Measure	Time frame	Description
Correlates of gut microbiome change between 2002-2024	2002-2024	Questionnaire-, biochemistry-, and health examination-derived correlates of gut microbiome change between 2002-2024.

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026